The agreement announced this morning to acquire a portfolio of gene therapy programs for rare disease from Pfizer accelerates our timeframe to bring this potentially transformative and curative treatment to patients. We look forward to welcoming Pfizer employees who have been driving this program forward, increasing our gene therapy team to over 80 specialists. Together with all my colleagues at Alexion, we are excited to continue our work developing enhanced platform in technologies, leveraging the expertise across a larger group to deliver life-changing medicines to patients where there are limited or no long-term treatment option. And with that, please advance to the next slide, and I will hand over the call to Pascal for closing remarks.